Author

Frank Dörje

EFFECTIVENESS, IMMUNOGENICITY, SAFETY AND PHARMACOECONOMIC ASPECTS FOLLOWING A SWITCH FROM REFERENCE INFLIXIMAB TO THE BIOSIMILAR SB2 IN INFLAMMATORY BOWEL DISEASE PATIENTS: A 6 MONTHS PROSPECTIVE COHORT STUDY

Sarah Fischer, Entcho Klenske, Heike Schmitt, Francesco Vitali, Simon Hirschmann, Franz Koch, Andreas Ramming, Sebastian Zundler, Sabine Krebs, Frank Dörje, Daniel Nagore, Sebastian Meyer, Wolfgang Uter, Markus F. Neurath, Raja Atreya

Item 1 - 1 / 1
1